/>

Andrea Abaurrea Larrañaga – Investigadora predoctoral en Biodonostia.

Online

23/04/21

13:30

Metastasis remains the main cause of death among breast cancer (BC) patients, as there are not effective therapies with curative intent for advanced BC. In particular, advanced triple negative (TN) BC has poor prognosis and lacks of targeted therapies. Therefore, finding new therapeutic targets for those cases is an unmet need with high clinical impact. In this context, the pro-inflammatory cytokine Oncostatin M (OSM) pathway is a promising therapeutic target as it is overexpressed in this subtype of tumours and associates with reduced overall survival. OSM signalling constitutes a central node for multicellular interactions between immune and non-immune stroma, and the epithelial compartment. The main sources of OSM are the myeloid cells, while OSMR is highly expressed by tumour cells and cancer associated fibroblasts (CAFs). The effects of OSMR activation by OSM are highly context and cell-type dependant, and the aim of this project is to understand the effects of OSM in breast cancer cells and to unravel its relative contribution to breast cancer progression and metastasis.